Geoffrey Hamilton-Fairley, CEO of Oncimmune
We are delighted that Oncimmune have today announced their IPO. The company have developed and patented a technology that detects cancer in its early stages, when the possibility of a cure is highest.
Balderton led a £5.25m round into Oncimmune in 2007, with Tim Bunting joining the board.
Congratulations to Geoffrey Hamilton-Fairley and the Oncimmune team, we look forward to their journey as a public company.